hemoglobinopathies
play

Hemoglobinopathies Diagnosis and management Morgan L. McLemore, M.D. - PDF document

Sep 19, 2023 •518 likes •767 views

Hemoglobinopathies Diagnosis and management Morgan L. McLemore, M.D. Hematology/Leukemia Department of Hematology and Oncology Winship Cancer Institute at Emory University mlmclem@emory.edu Disclosures Nothing relevant to report 1 Diffusion

  1. Hemoglobinopathies Diagnosis and management Morgan L. McLemore, M.D. Hematology/Leukemia Department of Hematology and Oncology Winship Cancer Institute at Emory University mlmclem@emory.edu Disclosures • Nothing relevant to report 1

  2. Diffusion insufficient for multicellular organisms O2 relatively insoluble in water O2 needs to “bound” then “released” 2

  3. 3

  4. 4

  5. Hemoglobin Properties • Soluble – As Long as 2 normal  and 2 normal  like chains – Charged residues are external in contact with water –  are relatively insoluble and function poorly – Unpaired  chains insoluble – Increases O2 in blood 70X • Cooperative Oxygen Binding • Allosteric Molecule 5

  6.     Hgb F Hgb A     6

  7. Adult Hemoglobin   Hemoglobin A >95%         Hemoglobin F <1.5%         Hemoglobin A2 <3.5%       Disorders of Hemoglobin • Hemoglobinopathies – Structural abnormalities – Thalassemias • Decreased production of Globin chains • Porphyrias – Defects in Heme synthesis 7

  8. Hemoglobinopathies • ~500,000 born each year with a clinically significant problem • ~7% carry a gene for Red Blood Cell defect Hgb Defect and or red cell membrane or enzyme defect Elisabeth Kohne Dtsch Arztebl Int 2011; 108(31 ‐ 32: 532 ‐ 540 8

  9. Hemoglobin Electrophoresis Alkalai 9

  10. 10

  11. Haemoglobin Reference Laboratories Titus HJ Huisman Hemoglobinopathy Laboratory at Georgia Regents University, Augusta, GA Boston University Hemoglobin Diagnostic Reference Laboratory Boston, MA Reference laboratory at Children’s Hospital of Oakland Research Institute, Oakland, CA When to suspect a Hemoglobinopathy • Microcytic anemia in the absence of iron deficiency • Non ‐ immune hemolytic anemia – After membrane, enzyme defects ruled out – Spherocytosis, eliptocytosis, G6PD and Pyruvate Kinase Deficiency – Heinz body positive – Unstable Hemoglobin • Polycythemia without obvious etiology and elevated Epo level • Cyanosis and methhemoglobinemia 11

  12. When to suspect a Hemoglobinopathy Adult Versus Pediatrics • In the Adult world we are more often dealing with more subtle disorders – Reaching a diagnosis is not always critical • Some may become evident during pregnancy • Exposure to Drugs may cause oxidative hemolysis Hemoblobinopathies Structural • 100s of mutations described • Majority of little clinical significance • High affinity and low affinity hemoglobin's • Methemoglobins – Fe+3 not Fe+2 • Unstable ‐ – Decreased solubility and/or susceptible to oxidative stress 12

  13. Hemoglobin S • 8 ‐ 10% African Americans heterozygotes • 30+% in areas of western Africa • Valine ‐ >Glutamic Acid codon 6 b Chain • Deoxygenated form polymerizes leading to red cell rigidity and hemolysis • Heterozygotes have no Phenotype – Severe Hypoxia ‐ climbing Mount Everest Hemoglobin S • Valine ‐ >Glutamic Acid codon 6 b Chain • Deoxygenated form polymerizes leading to red cell rigidity and hemolysis • Heterozygotes have no Phenotype – Severe Hypoxia ‐ climbing Mount Everest – Heat exposure in de ‐ conditioned individuals 13

  14. Hemoglobin C Hemoglobin E • Hemoglobin C – Lysine ‐ > Glutamic Acid Codon 6 Beta Chain – frequency 2 ‐ 3% AA High in central west Africa – Homozygotes have mild hemolytic anemia • Hemoglobin E – Glutamic Acid ‐ > Lysine Codon 26 beta chain – High frequency in SE Asia – Homozygotes have mild microcytic anemia • Significance is when combine with other Defects • Hgb SC, Hgb SE, Hgb E  Thalassemia • Misdiagnosed with iron deficiency Elisabeth Kohne Dtsch Arztebl Int 2011; 108(31 ‐ 32: 532 ‐ 540 14

  15. Thalassemias •  Thalassemia rarely a problem due to gene duplication •  Thalassemia due to multiple mutations • Promoter Mutations, Frame Shift, Splicing etc •  Normal production •  + decreased production from allele •  0 no production from allele 15

  16. Disorder Genoty MCV Anemia Hgb pe Electrophoresis Alpha Thalassemia  Silent Carrier Nl None Normal Very   Trait Low Mild Normal Common or In  African Americans   Hgb H Disease Low Moderate 5 ‐ 30% Hgb H    Major Low Fatal (fetal Hydrops) Beta Thalassemia   Trait Low Mild Hgb A2 increased Hgb F increased in 50%     Intermedia Low Moderate Hgb A2 increased Others Hgb F increased in 50%     Major Low Severe Hgb A Absent  Thalassemia Major Hematology Principles and Practice 2 nd Edition Hoffman Editor 16

  17.  Thalassemia Major Chronic Transfusion Protocol • 2 ‐ 4 units every 3 ‐ 4 weeks • – Pre ‐ Transfusion goal of hgb 9 ‐ 10 Suppress bone destruction and extramedullary hematopoiesis • If well Chelated Life expectancy into the 60s • – Annual quantification of hepatic and cardiac iron by MRI Normal Iron Intake ~60 ‐ 90mg/month • 3 units/ month is ~600mg • Body has no mechanism to excrete iron • 2 oral and one parenteral chelator available • – Frequent side effects – Often need two agents at once 17

  18. 30 Year Old Female • 4 weeks pregnant instructed to take iron • Italian descent • Baseline Hgb 10.8 MCV 62 • Hgb ELP A 93.7 A2 5.3 (1.5 ‐ 3.7) F 1 • Retic mildly elevated, Haptoglobin low/low normal •  0 /  beta thal minor • Hgb dropped to 8 during pregnancy • Supported with transfusions 18

  19. 27 Year Old Female • Diagnosis of beta thal • Indian descent • Baseline Hgb 8.5 MCV 77, ferritn 452 • Has required occasional transfusions in the past • Hgb ELP A 88.5 A2 4.3 (1.5 ‐ 3.7) F 7.2 •  + /  + beta thal intermedia 19

  20. beta thal intermedia • Clinical diagnosis •    + or other combinations • Hgb 8 ‐ 10, transfusions when stressed • May develop iron overload even in the absence of transfusions – May require chelation in later life • May develop extramedullary hematopoiesis • Splenectomy may improve Hgb significantly, but associated with marked increase rate of venous thromboembolic disease • Many respond to hydrea – Current patient 8.5 to 9.8 on 1 gm of hydrea HgbE/beta thal • Variable but similar to beta thal intermedia • SE Asia • Hgb E 25 ‐ 80%, F 6 ‐ 50%, A 5 ‐ 50% • Hgb 8 ‐ 10, transfusions when stressed • May develop iron overload even in the absence of transfusions – May require chelation in later life • May develop extramedullary hematopoiesis • Splenectomy may improve Hgb significantly, but associated with marked increase rate of venous thromboembolic disease • Many respond to hydrea 20

  21. 32 year old with microcytic anemia • Hgb 12.1, MCV 72.8 • Hgb ELP “normal” • Colonoscopy and bone marrow biopsy normal • African American • Hgb ELP A 98.2%, A2 1.5% (1.5 ‐ 3.7%) – Low normal A2 and ethinicity suggestive of  •  •  found in 20 ‐ 30% of African americans • Not an issue for family planning as trans deletion 18 year old student • Originally from Middle East • States he has Beta thal minor • Neonatal jaundice, received transfusion as infant • Hgb 9.5, MCV 64, Total Bili 1.8, Retic 240K/uL • Haptoglobin Normal ?!?! • HgbELP A 98%, A2 1.4% (1.5 ‐ 3.7%) • Abnormal hgb noted on HPLC 21

  22. Hemoglobin H Disease ‐ ‐ / ‐ a • Middle east and SE Asia • One operational alpha gene • Variable clinical course • Non Deletional mutations more likely to become • transfusion dependent over time (more comon in SE Asia) May develop similar complications as beta thal • intermdia (iron, VTE post splenectomy etc.), gall stones Prone to oxidative stress • Risk of hydrops in offspring • Does not respond to hydrea • Elisabeth Kohne Dtsch Arztebl Int 2011; 108(31 ‐ 32: 532 ‐ 540 22

  23. Conclusion • Diagnosis of a Hemoglobinopathy requires some degree of suspicion and close work with a dedicated laboratory. • Some disorders can present in adult hood and require close followup – Beta thal intermedia, Hgb H, E/beta thal Elisabeth Kohne Dtsch Arztebl Int 2011; 108(31 ‐ 32: 532 ‐ 540 23

More recommend